AssetMark Inc
NVS icon

AssetMark Inc’s Novartis NVS Stock Holding History

AssetMark Inc’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.4M Buy
442,978
+39,204
+10% +$5.88M 0.12% 146
2026
Q1 		$61.7M Sell
403,774
-2,457
-0.6% -$377K 0.13% 142
2025
Q4 		$56M Buy
406,231
+48,080
+13% +$6.3M 0.11% 151
2025
Q3 		$45.9M Buy
358,151
+38,243
+12% +$4.67M 0.1% 168
2025
Q2 		$38.7M Buy
319,908
+50,968
+19% +$5.74M 0.09% 182
2025
Q1 		$30M Buy
268,940
+3,258
+1% +$347K 0.08% 197
2024
Q4 		$25.9M Buy
265,682
+41,686
+19% +$4.45M 0.07% 213
2024
Q3 		$25.8M Buy
223,996
+10,290
+5% +$1.17M 0.07% 200
2024
Q2 		$22.8M Sell
213,706
-4,991
-2% -$501K 0.07% 208
2024
Q1 		$21.2M Buy
218,697
+2,398
+1% +$246K 0.07% 211
2023
Q4 		$21.8M Buy
216,299
+13,006
+6% +$1.26M 0.08% 191
2023
Q3 		$20.7M Buy
203,293
+4,524
+2% +$459K 0.08% 184
2023
Q2 		$20.1M Buy
198,769
+10,975
+6% +$1.1M 0.08% 190
2023
Q1 		$17.3M Buy
187,794
+403
+0.2% +$35.2K 0.07% 194
2022
Q4 		$17M Buy
187,391
+2,499
+1% +$210K 0.07% 190
2022
Q3 		$14.1M Buy
184,892
+13,214
+8% +$1.1M 0.07% 192
2022
Q2 		$14.5M Buy
171,678
+17,380
+11% +$1.52M 0.07% 196
2022
Q1 		$13.5M Buy
154,298
+143,165
+1,286% +$12.4M 0.06% 205
2021
Q4 		$974K Buy
11,133
+5,436
+95% +$451K ﹤0.01% 412
2021
Q3 		$466K Buy
5,697
+740
+15% +$66.6K ﹤0.01% 468
2021
Q2 		$452K Buy
4,957
+45
+0.9% +$4.01K ﹤0.01% 468
2021
Q1 		$420K Buy
4,912
+218
+5% +$19.6K ﹤0.01% 461
2020
Q4 		$443K Sell
4,694
-625
-12% -$54.6K ﹤0.01% 447
2020
Q3 		$463K Sell
5,319
-2,046
-28% -$177K ﹤0.01% 416
2020
Q2 		$643K Sell
7,365
-1,599
-18% -$138K ﹤0.01% 362
2020
Q1 		$739K Buy
8,964
+327
+4% +$29.2K 0.01% 352
2019
Q4 		$818K Sell
8,637
-944
-10% -$84.7K 0.01% 366
2019
Q3 		$833K Buy
9,581
+3,199
+50% +$287K 0.01% 330
2019
Q2 		$583K Buy
6,382
+385
+6% +$32.6K ﹤0.01% 339
2019
Q1 		$517K Buy
5,997
+395
+7% +$31.7K ﹤0.01% 341
2018
Q4 		$431K Buy
5,602
+72
+1% +$5.6K ﹤0.01% 353
2018
Q3 		$427K Buy
5,530
+581
+12% +$43K ﹤0.01% 370
2018
Q2 		$335K Buy
4,949
+629
+15% +$43.4K ﹤0.01% 386
2018
Q1 		$313K Buy
4,320
+1,702
+65% +$130K ﹤0.01% 390
2017
Q4 		$197K Buy
2,618
+384
+17% +$29K ﹤0.01% 473
2017
Q3 		$172K Sell
2,234
-102,421
-98% -$7.74M ﹤0.01% 488
2017
Q2 		$7.83M Buy
104,655
+508
+0.5% +$36K 0.1% 163
2017
Q1 		$6.93M Buy
104,147
+13,019
+14% +$868K 0.09% 167
2016
Q4 		$5.95M Buy
91,128
+3,309
+4% +$215K 0.09% 164
2016
Q3 		$6.21M Sell
87,819
-21,898
-20% -$1.6M 0.09% 152
2016
Q2 		$8.11M Buy
109,717
+4,041
+4% +$279K 0.14% 132
2016
Q1 		$6.86M Buy
105,676
+22,387
+27% +$1.52M 0.12% 134
2015
Q4 		$6.42M Buy
83,289
+21,774
+35% +$1.73M 0.12% 132
2015
Q3 		$5.07M Buy
61,515
+61,278
+25,856% +$5.45M 0.11% 127
2015
Q2 		$21K Buy
+237
New +$21.7K ﹤0.01% 460

Other funds holding NVS

Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
SI
Scharf Investments Los Gatos, California $3.03B AUM 7.75% 1-Year Est. Return
CPC
Cookson Peirce & Co Pittsburgh, Pennsylvania $3.04B AUM 94.11% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
GGI
Godsey & Gibb Inc Richmond, Virginia $1.22B AUM 27.93% 1-Year Est. Return
FWCM
Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return
QCM
QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

AssetMark Inc's NVS Position: Q2 2026 in Review

AssetMark Inc increased its Novartis (NVS) stake by 9.7% in Q2 2026, buying an estimated $5.88M and bringing the position to 442,978 shares worth $69.4M. The position accounts for 0.12% of the portfolio, ranked #146.

AssetMark Inc first reported a position in NVS in Q2 2015 and has held it in 45 quarters since. 734 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • AssetMark Inc held 442,978 shares of Novartis worth $69.4M as of Q2 2026.
  • AssetMark Inc bought 39,204 Novartis shares in Q2 2026, an estimated $5.88M.
  • Novartis made up 0.12% of AssetMark Inc's portfolio in Q2 2026, its #146 holding.
  • AssetMark Inc first reported a position in Novartis in Q2 2015 and has held it in 45 quarters since.
  • 734 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.